Spyre Therapeutics, Inc.
SYRE
$75.52
$0.480.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 35.34% | -1.35% | |||
| Gross Profit | -35.34% | 1.35% | |||
| SG&A Expenses | 21.51% | 7.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.30% | 0.50% | |||
| Operating Income | -32.30% | -0.50% | |||
| Income Before Tax | -10.36% | -459.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.36% | -459.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.36% | -459.15% | |||
| EBIT | -32.30% | -0.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -7.42% | -362.36% | |||
| Normalized Basic EPS | -51.35% | -349.87% | |||
| EPS Diluted | -7.42% | -362.36% | |||
| Normalized Diluted EPS | -51.35% | -349.87% | |||
| Average Basic Shares Outstanding | 4.61% | 24.29% | |||
| Average Diluted Shares Outstanding | 4.61% | 24.29% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||